Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma

Bertuccio, Paola; Malvezzi, Matteo; Carioli, Greta; Hashim, Dana; Boffetta, Paolo; El–Serag, Hashem B.; Vecchia, Carlo La; Negri, Eva

doi:10.1016/j.jhep.2019.03.013

Cited by 408 publications

(333 citation statements)

References 28 publications

Supporting

Mentioning

295

Contrasting

Order By: Relevance

“…This is the first international analysis to examine population‐based incidence rates of ICC and ECC as reported to high‐quality cancer registries. Two prior analyses, one examining international trends by using 32 countries and the other examining European rates, found an increase in ICC mortality in most countries, although data were from death certificates only and lacked morphology information . In addition, an international analysis of liver cancer performed by our group found that ICC incidence had increased in multiple countries between 1978 and 2007, but it did not examine ECC .…”

Section: Discussionmentioning

confidence: 97%

Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012

Florio

Ferlay

Znaor

et al. 2020

Cancer

180

156

View full text Add to dashboard Cite

BACKGROUND: Intrahepatic cholangiocarcinomas (ICCs) and extrahepatic cholangiocarcinomas (ECCs) are highly lethal bile duct tumors. Their incidence can be difficult to estimate because of changes in cancer coding over time. No studies to date have examined their global incidence and trends with high-quality topography-and histology-specific cancer registry data. Therefore, this study examined ICC and ECC incidence with the Cancer Incidence in Five Continents Plus database. METHODS: Regional and national cancer registry data were used to estimate age-standardized incidence rates (ASRs) per 100,000 person-years, 95% confidence intervals, and average annual percent changes (AAPCs) for ICC in 38 countries and for ECC in 33 countries from 1993 to 2012. ICC and ECC trends were tabulated and plotted by country. Rates versus birth cohort by age were plotted, and an age-period-cohort analysis was performed to assess age and cohort incidence rate ratios. RESULTS: The highest rates of ICC and ECC were in Asia, specifically South Korea (ASR for ICC, 2.80; ASR for ECC, 2.24), Thailand (ASR for ICC, 2.19; ASR for ECC, 0.71), and Japan (ASR for ICC, 0.95; ASR for ECC, 0.83). Between 1993 and 2012, incidence rates of both ICC and ECC increased in most countries. The largest ASR increases over the study period occurred in Latvia (AAPC, 20.1%) and China (AAPC, 11.1%) for ICC and in Thailand (AAPC, 8.8%) and Colombia (AAPC, 8.5%) for ECC. CONCLUSIONS: In the 20 years examined, ICC and ECC incidence increased in the majority of countries worldwide. ICC and ECC incidence may continue to increase because of metabolic and infectious etiologic factors. Efforts to further elucidate risk factors contributing to these increases in incidence are warranted. Cancer 2020;126:2666-2678.

show abstract

Section: Discussionmentioning

confidence: 97%

Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012

Florio

Ferlay

Znaor

et al. 2020

Cancer

180

156

View full text Add to dashboard Cite

show abstract

“…Cholangiocarcinomas (CCAs) are heterogeneous biliary malignancies characterized by dismal prognosis. the incidence and mortality rates of these cancers are rapidly increasing globally, currently accounting for~15% of all primary liver cancers and~3% of gastrointestinal malignancies [1][2][3]. According to their anatomical localization, CCAs are classified into intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA).…”

Section: Introductionmentioning

confidence: 99%

Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis

Lapitz

Arbelaiz

O’Rourke³

et al. 2020

Cells

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) comprises a group of heterogeneous biliary cancers with dismal prognosis. the etiologies of most CCAs are unknown, but primary sclerosing cholangitis (PSC) is a risk Cells 2020, 9, 721 2 of 33 factor. Non-invasive diagnosis of CCA is challenging and accurate biomarkers are lacking. We aimed to characterize the transcriptomic profile of serum and urine extracellular vesicles (EVs) from patients with CCA, PSC, ulcerative colitis (UC), and healthy individuals. Serum and urine EVs were isolated by serial ultracentrifugations and characterized by nanoparticle tracking analysis, transmission electron microscopy, and immunoblotting. EVs transcriptome was determined by Illumina gene expression array [messenger RNAs (mRNA) and non-coding RNAs (ncRNAs)]. Differential RNA profiles were found in serum and urine EVs from patients with CCA compared to control groups (disease and healthy), showing high diagnostic capacity. the comparison of the mRNA profiles of serum or urine EVs from patients with CCA with the transcriptome of tumor tissues from two cohorts of patients, CCA cells in vitro, and CCA cells-derived EVs, identified 105 and 39 commonly-altered transcripts, respectively. Gene ontology analysis indicated that most commonly-altered mRNAs participate in carcinogenic steps. Overall, patients with CCA present specific RNA profiles in EVs mirroring the tumor, and constituting novel promising liquid biopsy biomarkers.

show abstract

“…Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer after hepatocellular carcinoma. The incidence of ICC is increasing worldwide, with an average 2.3% annual increase . The 5‐year survival rate for patients with ICC is less than 10%, partly because approximately 80% of patients are diagnosed at a late stage when surgery is no longer a treatment option .…”

Section: Introductionmentioning

confidence: 99%

Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study

et al. 2020

View full text Add to dashboard Cite

Background and Aims: The prognosis of intrahepatic cholangiocarcinoma (ICC) after radical resection is far from satisfactory; however, the clinical value of adjuvant therapy (AT) remains controversial. This multicenter study aimed to evaluate the clinical value of AT and identify potential patients who would be benefited from AT. Methods: Data from ICC patients who underwent radical resection were retrospectively collected from 12 hepatobiliary centers in China between December 2012 and December 2015. Patients were divided into AT and non-AT groups based on whether AT was administered or not. Overall survival (OS) and disease-free survival (DFS)were analyzed using the Kaplan-Meier method before and after 1:2 propensity score matching (PSM). Subgroup analyses were conducted based on the established staging systems. | 2675WANG et Al.

show abstract

Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma

Cited by 408 publications

References 28 publications

Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012

Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012

Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis

Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study

Contact Info

Product

Resources

About